Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04335383

Acronym

ABAC-IBS

Enrollment

Registered

2020-04-06

Start date

2020-10-05

Completion date

2026-10-31

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi-antibiotic Resistance, Pseudomonas Aeruginosa

Keywords

Pseudomonas aeruginosa, monoclonal antibody

Brief summary

Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment. The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.

Interventions

BIOLOGICALIsolation of anti-Pseudomonas antibodies from type B lymphocytes

Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies) * Patient with weight ≥ 32kg. * With a follow-up visit at Grenoble University Hospital with a blood sampling for its care * Having given its written no objection to participate in the prospective phase of this project

Exclusion criteria

* Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)

Design outcomes

Primary

Measure	Time frame	Description
Isolation of recombinant human monoclonal antibodies against Pseudomonas aeruginosa	1 day	Detection of binding of recombinant antibodies to Pseudomonas aeruginosa target proteins by ELISA assay.

Secondary

Measure	Time frame	Description
Isolation of functional antibodies against Pseudomonas aeruginosa	1 day	Percentage of inhibition of Pseudomonas aeruginosa infection by antibodies using an in vitro model of cell infection and virulence. Percentage of lysis of Pseudomonas aeruginosa in the presence of recombinant IgG, complement and macrophages in an opsonophagocytosis assay

Countries

France

Contacts

Primary ContactYvan CASPAR, Dr

ycaspar@chu-grenoble.fr+33 4 76 76 54 79

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026